TY - JOUR
T1 - HtrA serine proteases as potential therapeutic targets in cancer
AU - Chien, Jeremy
AU - Campioni, Mara
AU - Shridhar, Viji
AU - Baldi, Alfonso
PY - 2009/6
Y1 - 2009/6
N2 - The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.
AB - The human HtrA family of serine proteases consists of four members: HtrA1, HtrA2, HtrA3 and HtrA4. Although prokaryotic HtrA proteins are well characterized in their dual roles as chaperones and proteases that degrade misfolded proteins in the periplasm, some members of mammalian HtrA proteins are described as potential modulators of programmed cell death and chemotherapy-induced cytotoxicity. Goal of this review article is to describe the molecular alterations associated with these HtrA serine proteases and how these alterations may be associated with tumor behavior and response to chemotherapy. We will also discuss evidence that chemotherapeutic drugs regulate the expression and activation of HtrA serine proteases and that these proteases contributes to programmed cell death. Finally, we will discuss the potential role of epigenetic therapy in targeting the expression and activation of HtrA serine proteases and the mechanisms by which these proteases enhance cytotoxic effect of conventional chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=67649305413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649305413&partnerID=8YFLogxK
U2 - 10.2174/156800909788486704
DO - 10.2174/156800909788486704
M3 - Review article
C2 - 19519315
AN - SCOPUS:67649305413
SN - 1568-0096
VL - 9
SP - 451
EP - 468
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
IS - 4
ER -